Celgene receives EC approvals for REVLIMID® (lenalidomide) and IMNOVID® combination
Celgene announced the EC has approved two new triplet regimens based on Celgene’s proprietary IMiD treatments, REVLIMID (lenalidomide) and IMNOVID (pomalidomide). REVLIMID in combination with bortezomib and dexamethasone is indicated for treatment of adult patients with untreated multiple myeloma. May 16, 2019